Pediatrix Medical Group (NYSE:MD) Price Target Raised to $15.00

Pediatrix Medical Group (NYSE:MD) had its price target boosted by Mizuho from $13.00 to $15.00 in a report published on Tuesday,Benzinga reports. They currently have a neutral rating on the stock.

A number of other brokerages have also recently commented on MD. Jefferies Financial Group boosted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. UBS Group boosted their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Truist Financial raised their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $16.10.

Pediatrix Medical Group Price Performance

MD opened at $14.75 on Tuesday. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -4.82, a price-to-earnings-growth ratio of 2.08 and a beta of 1.55. The stock has a fifty day simple moving average of $12.84 and a two-hundred day simple moving average of $10.00. Pediatrix Medical Group has a 12-month low of $6.62 and a 12-month high of $16.41.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. Pediatrix Medical Group’s revenue was up .9% on a year-over-year basis. During the same period last year, the company posted $0.29 EPS. Research analysts predict that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the transaction, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. This represents a 18.52 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,808 shares of company stock valued at $751,277. Company insiders own 2.00% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Large investors have recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in shares of Pediatrix Medical Group by 302.9% in the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock worth $1,646,000 after purchasing an additional 106,817 shares during the period. Geode Capital Management LLC increased its stake in Pediatrix Medical Group by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,936,751 shares of the company’s stock worth $22,452,000 after buying an additional 45,155 shares during the period. M&T Bank Corp boosted its position in Pediatrix Medical Group by 20.1% in the 3rd quarter. M&T Bank Corp now owns 85,264 shares of the company’s stock valued at $988,000 after buying an additional 14,247 shares during the period. Jane Street Group LLC boosted its position in Pediatrix Medical Group by 54.0% in the 3rd quarter. Jane Street Group LLC now owns 303,283 shares of the company’s stock valued at $3,515,000 after buying an additional 106,332 shares during the period. Finally, Weiss Asset Management LP grew its stake in Pediatrix Medical Group by 50.5% in the 3rd quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after acquiring an additional 306,143 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.